Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# IDDRIVE

A public-private partnership for the estimation of brand-specific COVID-19 vaccine effectiveness in Europe

## Sitemaps

- [XML Sitemap](https://iddrive.eu/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Viral Pathogen-Specific Severe Acute Respiratory Infections in Hospitalised Adults in Europe: Epidemiological Findings from the id.DRIVE Study 2024-2025](https://iddrive.eu/2026/08/03/viral-pathogen-specific-severe-acute-respiratory-infections-in-hospitalised-adults-in-europe-epidemiological-findings-from-the-id-drive-study-2024-2025/) - Katherine Newell, Nikki Vroom, Cátia Marques, Ekaterina Maslova, Farid L Khan, Kok-Yew Ngew, Hannah R Volkman, Chengbin Wang, Juan V Hernandez-Villena, Negar Aliabadi, Elizabeth Begier, Jennifer L Nguyen, Hollie Dunford, Somsuvro Basu, Andrés Antón, Susana Otero-Romero, Irma Casas, Elisa Martró, Beate Grüner, Giancarlo Icardi, Federico Martinón-Torres, Ainara Mira-Iglesias, Carlos M Oñoro-López, Alejandro Orrico-Sánchez, Oleguer Parés-Badell,
- [id.DRIVE advances preparations for the 2026–2027 season with successful site initiation visits in Canada](https://iddrive.eu/2026/08/03/id-drive-advances-preparations-for-the-2026-2027-season-with-successful-site-initiation-visits-in-canada/) - The id.DRIVE consortium has taken another important step in the expansion of its international study network with the successful completion of site initiation visits at three participating centres in Canada in July. The on-site visits were conducted at the Mt Sinai Hospital in Toronto, coordinator of the Toronto Invasive Bacterial Diseases Network (TIBDN), and the Ottawa
- [The 2025–2026 id.DRIVE studies reached the 10,000-patient recruitment milestone, bringing total enrolment over 40,000 participants since 2021.](https://iddrive.eu/2026/06/30/the-2025-2026-id-drive-studies-reached-the-10000-patient-recruitment-milestone-bringing-total-enrolment-over-40000-participants-since-2021/) - The id.DRIVE partnership is pleased to announce that recruitment for the 2025–2026 epidemiological year already reached over 10,000 patients—hitting our total target for the season 2025-2026. As of 26 June 2026, 11,545 SARI patients had already been recruited across 13 sites in five countries (France, Germany, Italy, Spain, and United Kingdom) exceeding the total recruitment
- [id.DRIVE Site Investigators Meeting 2026: advancing study quality, operational efficiency and preparedness](https://iddrive.eu/2026/04/28/id-drive-site-investigators-meeting-2026-advancing-study-quality-operational-efficiency-and-preparedness/) - On 21 April 2026,the id.DRIVE study team, site collaborators and partners convened in Munich, Germany, for the annual id.DRIVE Site Investigators Meeting. The meeting provided an opportunity to review the ongoing 2025–2026 season progress, share interim surveillance results, and align on key operational improvements shaping the future of the network. With contributions from more than 30 investigators from the id.DRIVE network representing 6
- [id.DRIVE announces strategic expansion of study network to Canada](https://iddrive.eu/2026/03/24/id-drive-announces-strategic-expansion-of-study-network-to-canada/) - The id.DRIVE consortium is proud to announce the expansion of its observational infectious diseases research platform to Canada, marking a major milestone in the study network’s international growth. In 2024, consortium partners agreed to assess the feasibility of extending id.DRIVE’s observational studies beyond Europe. This strategic decision responds to the growing demand for increased geographical
- [id.DRIVE showcases RSV research at ReSViNET 2026 conference in Italy](https://iddrive.eu/2026/03/06/id-drive-showcases-rsv-research-at-resvinet-2026-conference-in-italy/) - From 17–20 February 2026, the ReSViNET - Respiratory Syncytial Virus (RSV) Foundation held its 9thinternational conference in Rome, bringing together global experts dedicated to advancing research on RSV. The id.DRIVE consortium actively engaged in this major scientific event, reinforcing its commitment to high-quality RSV surveillance and vaccine effectiveness research. Advancing RSV knowledge through multi-stakeholder collaborationThe conference provided
- [Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform](https://iddrive.eu/2026/02/24/durability-of-the-bnt162b2-xbb1-5-adapted-vaccine-against-jn-1-hospitalisation-in-europe-october-2023-to-august-2024-a-test-negative-case-control-study-using-the-id-drive-platform/) - Hannah R. Volkman ,Leonie de Munter, Jennifer L. Nguyen, Thao M. P. Tran, Marianna Mitratza, Cátia Marques, Laura Choi, Srinivas Valluri, Jingyan Yang, Andrés Antón, Irma Casas, Eduardo Conde-Sousa, Laura Drikite, Beate Grüner, Giancarlo Icardi, Gerrit Luit ten Kate, Charlotte Martin, Ainara Mira-Iglesias, Alejandro Orrico-Sánchez, Susana Otero-Romero, Gernot Rohde, Luis Jodar, John M. McLaughlin &
- [id.DRIVE launches pilot study to assess potential underestimation of RSV, hMPV, and PIV detection rates.](https://iddrive.eu/2026/01/14/id-drive-launches-pilot-study-to-assess-potential-underestimation-of-rsv-hmpv-and-piv-detection-rates/) - id.DRIVE launched a new prospective cohort pilot study to investigate whether respiratory syncytial virus (RSV) and other respiratory viruses may be underestimated when relying solely on nasopharyngeal swabs for diagnosis. The primary objective is to compare the detection rates of RSV, human metapneumovirus (hMPV), and parainfluenza virus (PIV) using a multi-specimen collection approach (incorporating oropharyngeal
- [id.DRIVE celebrates 5 years of advancing respiratory infectious diseases and vaccine research in Europe](https://iddrive.eu/2025/12/12/id-drive-celebrates-5-years-of-advancing-respiratory-infectious-diseases-and-vaccine-research-in-europe/) - 7 December 2025 — Today marks the five-year anniversary of id.DRIVE, a milestone that reflects half a decade of commitment to strengthening Europe’s infectious disease surveillance and post-marketing vaccine effectiveness assessment. Launched on 7 December 2020 as COVIDRIVE, the initiative was created at the height of the COVID-19 pandemic to provide rapid, high-quality evidence on
- [id.DRIVE partners gather in Leuven for the 2025 Steering Committee meeting](https://iddrive.eu/2025/12/01/id-drive-partners-gather-in-leuven-for-the-2025-steering-committee-meeting/) - On 12 and 13th of November, the id.DRIVE Steering Committee convened in Leuven, Belgium, for its annual in-person meeting. Over two productive days, all partners came together to reflect on the past season, evaluate the progress of the ongoing studies, and shape the future of the id.DRIVE partnership. The meeting opened with a comprehensive review of
- [Precautionary Health Behaviours as Potential Confounders in COVID-19 Vaccine Effectiveness Studies](https://iddrive.eu/2025/10/14/precautionary-health-behaviours-as-potential-confounders-in-covid-19-vaccine-effectiveness-studies/) - Chloé Wyndham-Thomas, Leonie de Munter, Kok Yew Ngew, Sanskruti Gaikwad, Konstantina Chatzikonstantinidou, Antonio Carmona, Charlotte Martin, Gerrit Luit ten Kat, Nicolas Praet, Wilhelmine Meeraus, Matthew D. Rousculp, and Kaatje Bollaerts Vaccines (2025)https://doi.org/10.3390/vaccines13101047
- [The id.DRIVE partnership starts a viral respiratory infections surveillance study in adults hospitalised for severe acute respiratory infection in Europe](https://iddrive.eu/2024/07/26/the-id-drive-partnership-starts-a-viral-respiratory-infections-surveillance-study-in-adults-hospitalised-for-severe-acute-respiratory-infection-in-europe/) - We are thrilled to announce that we started in July 2024 the id.DRIVE surveillance study in Europe. The surveillance study is a multi-country hospital-based study which monitors viral respiratory infections in adults hospitalised for severe acute respiratory infection (SARI). This sentinel study is a common data collection which builds the foundation for a sustainable study-ready
- [First face-to-face COVIDRIVE Steering Committee meeting](https://iddrive.eu/2022/12/05/first-face-to-face-covidrive-steering-committee-meeting/) - On November 14th and 15th, 2022, the city of Valencia became the epicentre of COVIDRIVE Partnership discussions. The members of the COVIDRIVE Steering Committee (SC) connected to share the vaccine company-specific COVID-19 vaccine effectiveness interim results, to review all progress made and to brainstorm about vaccination preparedness and sustainability of the COVIDRIVE consortium. The group met at the Hotel Las Arenas and went through a packed two-day agenda.
- [AstraZeneca has published its first COVIDRIVE results in Lancet Regional Health Europe.](https://iddrive.eu/2023/06/30/astrazeneca-has-published-its-first-covidrive-results-in-lancet-regional-health-europe-2/) - The study concluded that primary-series vaccination with AstraZeneca´s COVID-19 vaccine confers protection against COVID-19 hospitalisation with enduring levels of vaccine effectiveness through ≥6 months. Find out more here.
- [COVIDRIVE has reached a milestone: enrolment of over 10,000 patients](https://iddrive.eu/2023/07/14/covidrive-has-reached-a-milestone-enrolment-of-over-10000-patients/) - We are pleased to announce that the first COVIDRIVE study has recruited 10,038 patients across 17 hospitals in 5 European countries. This high recruitment number is important for collection of real-world evidence. We would like to thank all participants and their families for taking part in this study and trusting us with their personal data. We would also like to acknowledge the teams at the
- [id.DRIVE has activated a new Study Contributor (study site) in Italy](https://iddrive.eu/2024/03/01/id-drive-has-activated-a-new-study-contributor-study-site-in-italy/) - id.DRIVE has activated Luigi Sacco Hospital on February 28th, 2024. Luigi Sacco Hospital is located in north Milan, Italy, and has over 500 beds. It has started recruitment for the ongoing COVID-19 vaccine effectiveness study and will also take part in the surveillance study which is planned to start summer 2024.
- [id.DRIVE welcomes 3 new members to its Independent Scientific Committee](https://iddrive.eu/2024/04/09/id-drive-welcomes-3-new-members-to-its-independent-scientific-committee/) - With id.DRIVE´s expansion of scope beyond COVID-19 and broadened studies’ portfolio, we recently extended the breadth of expertise and number of members of our Independent Scientific Committee (ISC). We are pleased to announce that Prof. Harish Nair, Assoc. Prof. Sheena Sullivan and Prof. Peter Smith are now part of id.DRIVE´s ISC. They have joined Dr.
- [The id.DRIVE studies reach 25,000 patients — A major milestone on our mission to build a large and sustainable platform for respiratory pathogens and vaccines research](https://iddrive.eu/2025/10/03/the-id-drive-studies-reach-25000-patients-a-major-milestone-on-our-mission-to-build-a-large-and-sustainable-platform-for-respiratory-pathogens-and-vaccines-research/) - We are proud to announce that the id.DRIVE partnership has officially recruited 25,000 patients across our three studies (surveillance, COVID-19 and RSV vaccine effectiveness) — a remarkable milestone that underscores the strength of our collaboration and the commitment of our partners, study contributors, and participants. Since September 2021, the platform that began with the COVIDRIVE COVID-19 vaccine
- [Prof. Philippe Beutels joined id.DRIVE’s Independent Scientific Committee](https://iddrive.eu/2025/05/23/prof-philippe-beutels-joined-id-drives-independent-scientific-committee/) - We are pleased to announce that Prof. Philippe Beutels joined the Independent Scientific Committee of id.DRIVE. Prof. Beutels brings expertise on infectious diseases health economic and vaccination. This broadens our expertise into new interdisciplinary fields that are highly relevant to the id.DRIVE consortium. Philippe is Professor of Health Economics at University of Antwerp. He is
- [The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative](https://iddrive.eu/2025/09/24/the-value-of-public-private-collaborative-real-world-evidence-platforms-to-monitor-vaccine-performance-post-authorization-drive-a-european-initiative/) - Díez-Domingo J, Torcel-Pagnon L, Carmona A, Launay O, Dos Santos G, Rizzo C, Haag M, Stuurman A, Nauta J, Vannacci A, de Lusignan S, Del Rey E, Levi M, Lina B, Bellino S, Nye S, Neels P, Nohynek H, Mahé C; DRIVE consortium. Expert Rev Vaccines. 2022 Dec;21(12):1701-1710. doi: 10.1080/ 14760584.2022.2137144. PMID: 36261918.https://www.tandfonline.com/doi/10.1080/14760584.2022.2137144?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
- [Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform” (pre-print).](https://iddrive.eu/2025/09/25/durability-of-the-bnt162b2-xbb-1-5-adapted-vaccine-against-jn-1-hospitalisation-in-europe-october-2023-to-august-2024-a-test-negative-case-control-study-using-the-id-drive-platform-pre-pri/) - HR Volkman, L de Munter, JL Nguyen, TMP Tran, M Mitratza, C Marques, L Choi, S Valluri, J Yang, A Antón, I Casas, E Conde-Sousa, L Drikite, B Grüner, G Icardi, G Luit ten Kate, C Martin, A Mira-Iglesias, A Orrico-Sánchez, S Otero-Romero, G Rohde, L Jodar, JM McLaughlin, K Bollaerts. MedRxiv (2025) – preprinthttps://doi.org/10.1101/2025.05.02.25326904
- [Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis.](https://iddrive.eu/2025/09/26/protection-against-covid-19-hospitalisation-conferred-by-primary-series-vaccination-with-azd1222-in-non-boosted-individuals-first-vaccine-effectiveness-results-of-the-european-covidrive-study-and-met/) - Wilhelmine Meeraus, Leonie de Munter, Christen M. Gray, Akshat Dwivedi, Chloé Wyndham-Thomas, Mario Ouwens, Wendy Hartig-Merkel, Laura Drikite, Griet Rebry, Antonio Carmona, Anke L. Stuurman, Thi Yen Chi Nguyen, Guillermo Mena, Ainara Mira-Iglesias, Giancarlo Icardi, Susana Otero-Romero, Sebastian Baumgartner, Charlotte Martin, Sylvia Taylor, and Kaatje Bollaerts. Protection against COVID-19 hospitalisation conferred by primary-series vaccination with
- [Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVEplatform.](https://iddrive.eu/2025/09/27/effectiveness-of-the-bnt162b2-xbb-1-5-adapted-vaccine-against-covid-19-hospitalization-related-to-the-jn-1-variant-in-europe-a-test-negative-case-control-study-using-the-id-driveplatform/) - Jennifer L. Nguyen, Marianna Mitratza, Hannah R. Volkman, Leonie de Munter, Thao Mai Phuong Tran, Catia Marques, Mustapha Mustapha, Srinivas Valluri, Jingyan Yang, Andrés Antón, Irma Casas, Eduardo Conde-Sousa, Laura Drikite, Beate Grüner, Giancarlo Icardi, Gerrit Luit ten Kate, Charlotte Martin, Ainara Mira-Iglesias, Alejandro Orrico-Sánchez, Susana Otero-Romero, Gernot Rohde, Luis Jodar, John M. McLaughlin, and
- [Effectiveness of the AZD1222 Vaccine against COVID-19 hospitalisation in Europe: Final results from the COVIDRIVE test-negative case-control study. ](https://iddrive.eu/2025/09/28/effectiveness-of-the-azd1222-vaccine-against-covid-19-hospitalisation-in-europe-final-results-from-the-covidrive-test-negative-case-control-study/) - Leonie de Munter, Wilhelmine Meeraus, Akshat Dwivedi, Marianna Mitratza, Chloé Wyndham-Thomas, Lucy Carty, Mario Ouwens, Wendy Hartig-Merkel, Laura Drikite, Griet Rebry, Irma Casas, Ainara Mira-Iglesias, Giancarlo Icardi, Susana Otero-Romero, Sebastian Baumgartner, Charlotte Martin, Xavier Holemans, Gerrit Luit ten Kate, Kaatje Bollaerts, and Sylvia Taylor. European Journal of Public Health (2025)https://doi.org/10.1093/eurpub/ckae219
- [Vaccine effectiveness of JCOVDEN single-dose against COVID-19 hospitalisation in Europe: An id.DRIVE test-negative case-control study.](https://iddrive.eu/2025/09/29/vaccine-effectiveness-of-jcovden-single-dose-against-covid-19-hospitalisation-in-europe-an-id-drive-test-negative-case-control-study/) - Chloé Wyndham-Thomas, E. Claire Newbern, Ainara Mira-Iglesias, Akshat Dwivedi, Alejandro Orrico Sánchez, Andrés Antón, Charlotte Martin, Giancarlo Icardi, Irma Casas, Kok Yew Ngew, Laura Drikite, Leonie de Munter, Gerrit Luit ten Kate, Nikki Vroom, Sebastian Baumgartner, Susana Otero-Romero, Xavier Holemans, Kaatje Bollaerts, and Nicolas Praet Journal of Infection and Public Health (2025)https://doi.org/10.1016/j.jiph.2025.102700
- [Launch of the id.DRIVE respiratory syncytial virus (RSV) vaccine effectiveness study with the first site activation on 29 August 2024.](https://iddrive.eu/2024/09/26/launch-of-the-id-drive-respiratory-syncytial-virus-rsv-vaccine-effectiveness-study-with-the-first-site-activation-on-29-august-2024/) - Universitätsklinikum Frankfurt in Germany was the first study site to be activated for the RSV vaccine effectiveness study in adults hospitalised with severe acute respiratory infection (SARI) in Europe. Other study sites will be activated in Europe and in the United Kingdom throughout the coming months. This study will continuously monitor different marketed RSV vaccines’
- [id.DRIVE’s third site investigator meeting took place on 13 April in Vienna, Austria](https://iddrive.eu/2025/05/23/id-drives-third-site-investigator-meeting-took-place-on-13-april-in-vienna-austria/) - On 13 April 2025, our third site investigator meeting convened 16 representatives from 11 sites across five countries, along with members of the Co-Coordination team (P95 and FISABIO) and pharmaceutical partners, at the Zoku Hotel in Vienna, Austria. The event was organized in parallel of the ESCMID 2025 conference. The full-day session focused on fostering
- [Don’t miss out on the latest id.DRIVE publications: three peer-reviewed articles on COVID-19 vaccine effectiveness based on data from the id.DRIVE partnership have been published in early 2025.](https://iddrive.eu/2025/05/23/dont-miss-out-on-the-latest-id-drive-publications-three-peer-reviewed-articles-on-covid-19-vaccine-effectiveness-based-on-data-from-the-id-drive-partnership-have-been-published-in-early-2025/) - The beginning of 2025 has been a productive publication period for id.DRIVE, with three peer-reviewed publications highlighting COVID-19 vaccine effectiveness across Europe. These results reinforce the id.DRIVE’s role in generating high-quality evidence to inform public health decisions. “Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative
- [id.DRIVE expands its study network to the United Kingdom with the activation of Imperial College London as a new study site](https://iddrive.eu/2025/05/23/id-drive-expands-its-study-network-to-the-united-kingdom-with-the-activation-of-imperial-college-london-as-a-new-study-site/) - We are pleased to announce that the id.DRIVE study network has officially expanded its reach to the United Kingdom with the activation of a new site: Imperial College London, which includes St. Mary’s Hospital and Charing Cross Hospital. The site was successfully activated on 4th of April 2025 following a productive site initiation visit. Imperial
- [id.DRIVE's study network expands to France with the activation of Henri Mondor hospital site in Paris](https://iddrive.eu/2025/07/02/id-drives-study-network-expands-to-france-with-the-activation-of-henri-mondor-hospital-site-in-paris/) - In a major milestone, the id.DRIVE study network has officially expanded its presence in Europe with the activation of its first site in France. The Hôpital Henri Mondor site works in collaboration with two other hospitals in Paris : Hôpital Albert Chenevier and Hôpital Georges-Clemenceau. The Henri Mondor hospital site was successfully activated on the
- [The id.DRIVE Partnership launches its 2025–2026 Epidemiological Year with three studies](https://iddrive.eu/2025/09/01/the-id-drive-partnership-launches-its-2025-2026-epidemiological-year-with-three-studies/) - The 1st September 2025 marks the official start of the 2025–2026 epidemiological year for the id.DRIVE studies, kicking off another year dedicated to tracking respiratory infectious diseases and advancing collaborative science in Europe. Months of preparation and dedication have led to the activation of 31 hospitals, representing 13 Study Contributors,in France, Germany, Italy, Spain and
- [Poster presentation during ESCMID Global 2024](https://iddrive.eu/2024/04/27/poster-presentation-during-escmid-global-2024/) - During the 34th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) held in Barcelona, Spain on 27-30 April 2024, the id.DRIVE co-coordination team presented a poster on the id.DRIVE consotium, its transition from COVIDRIVE and general overview of ongoing and future studies.
- [Second in-person Site Investigator meeting](https://iddrive.eu/2024/04/28/second-in-person-site-investigator-meeting/) - On 28 April 2024, the second in-person Study Contributor (Site) Investigator meeting took place as a satellite meeting during the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain. Team members from the following current Spanish and Italian Study Contributors attended the meeting: Valencia Hospital Network for the Study of Infectious Diseases
- [COVIDRIVE expands its scope of studies and becomes id.DRIVE: new European partnership for burden and effectiveness studies on infectious diseases.](https://iddrive.eu/2024/01/16/covidrive-expands-its-scope-of-studies-and-become-id-drive-new-european-partnership-for-burden-and-effectiveness-studies-on-infectious-diseases/) - id.DRIVE is a Public-Private-Partnership, which consists of a unique consortium of pharmaceutical companies, public health institutes and research groups who are joining forces to monitor infectious diseases and effectiveness of related pharmaceutical products in real-life in Europe. This is achieved by several pharmaceutical companies co-funding a research network of hospitals. id.DRIVE leverages the COVID-19 vaccine
- [Second annual face-to-face COVIDRIVE Steering Committee meeting](https://iddrive.eu/2023/11/29/second-annual-face-to-face-covidrive-steering-committee-meeting/) - On November 28th and 29th, 2023, the members of the COVIDRIVE Steering Committee met in Valencia, Spain to discuss the overall Partnership as well as ongoing and future studies. Partners’ representatives and Liz Miller, member of the Independent Scientific Committee, joined both in person or virtually for an intense two-day meeting. The Co-coordination team with
- [Site Investigators’ meeting](https://iddrive.eu/2023/12/14/site-investigators-meeting/) - COVIDRIVE´s second virtual site investigators meeting took place on December 14th, 2023. We welcomed participants from sites in Spain, Italy, Belgium and Germany . The study progress was presented: since the study started in September 2021, we have recruited over 10,237 patients across 11 sites (19 hospitals) in five EU countries. We took the opportunity
- [Study investigator meeting in Copenhagen](https://iddrive.eu/2023/04/16/study-investigator-meeting-in-copenhagen/) - On 16 April, 2023, during the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark, a hybrid study investigator meeting took place. Participants attended from FISABIO, Hospital Universitario Germans Trias i Pujol, Hospital Universitario Vall d’Hebron and Hospital Universitario Josep Trueta (Spain), Grand Hôpital de Charleroi and CHU Saint Pierre Hospital Brussels
- [New public-private partnership COVIDRIVE to assess brand-specific COVID-19 vaccine effectiveness in Europe](https://iddrive.eu/2021/07/19/new-public-private-partnership-covidrive-to-assess-brand-specific-covid-19-vaccine-effectiveness-in-europe/) - 19/07/2021 – A new public-private partnership – COVIDRIVE – announced today that it will begin studies to assess the effectiveness of multiple COVID-19 vaccines in Europe to support the region’s public health response and to address the vaccine companies’ regulatory obligations. This multi-stakeholder partnership brings together public institutions, small medium enterprises and vaccine companies, including FISABIO (Spain), P95 (Belgium), THL (Finland), AstraZeneca (UK), CureVac (Germany), Janssen (Belgium), Sanofi-Pasteur (France) and GSK (Belgium).

## Pages

- [Home](https://iddrive.eu/) - id.DRIVE open partnership An open public-private partnership to facilitate the conduct of observational studies on infectious diseases, related vaccines, preventive measures, therapeutics and diagnostics.Interested in important updates on the partnership?Subscribe to our newsletter by contacting us WHAT IS id.DRIVE? id.DRIVE is a privately funded not-for-profit open public-private partnership that facilitates the conduct of observational and
- [Study Contributors](https://iddrive.eu/study-contributors/) - Study Contributors id.DRIVE’s Study Contributors network consists of 26 Study Contributors (Study Sites) including 57 hospitals from 8 different countries:Austria, Belgium, Canada, France, Germany, Italy, Spain and the United Kingdom. id.DRIVE is open to include new study sites in its network. Interested to join, contact us Centro Interuniversitario per la Ricerca sull’Influenza e le altre
- [Study documents and tools](https://iddrive.eu/study-documents/) - id.DRIVE overview:ESCMID April 2026 posterSurveillance Study:Surveillance Study protocol V2.0 21 Apr 2025Surveillance Study protocol V1.0 21 Mar 2024COVID-19 Vaccine Effectiveness Master protocols:COVID-19 Vaccine Effectiveness protocol V7.0_21 Feb 2025COVID-19 Vaccine Effectiveness protocol V6.0_21 Mar 2024COVID-19 Vaccine Effectiveness protocol V5.0_18 Sep 2023COVID-19 Vaccine Effectiveness protocol V4.0_10 Oct 2022COVID-19 Vaccine Effectiveness protocol V3.3_23 Dec 2021COVID-19 Vaccine Effectiveness protocol
- [Studies](https://iddrive.eu/studies/) - STUDIES id.DRIVE carries out different studies under a common data collection. Three studies are currently running: a respiratory viruses surveillance study, a COVID-19 Vaccine Effectiveness study (CVE), and a respiratory syncytial virus (RSV VE) Vaccine Effectiveness study.Patient recruitment started in September 2021 for the COVID-19 CVE study. The common data collection was launched on 26
- [Deliverables](https://iddrive.eu/deliverables/) - PUBLICATIONS Viral Pathogen-Specific Severe Acute Respiratory Infections in Hospitalised Adults in Europe: Epidemiological Findings from the id.DRIVE Study 2024-2025 Katherine Newell, Nikki Vroom, Cátia Marques, Ekaterina Maslova, Farid L Khan, Kok-Yew Ngew, Hannah R Volkman, Chengbin Wang, Juan V Hernandez-Villena, Negar Aliabadi, Elizabeth Begier, Jennifer L Nguyen, Hollie Dunford, Somsuvro Basu, Andrés Antón, Susana Otero-Romero, Irma
- [Contact](https://iddrive.eu/contact/) - Join the id.DRIVE network! Whether you are a pharmaceutical company, researcher, or study site, we are excited to hear from your and expand our partnership. If you need more information on how our governance works, or look for more details on the id.DRIVE studies, our team can provide you with more documentation, upon request. 📬
- [Newsroom2](https://iddrive.eu/newsroom2/) - LATEST NEWS Newsroomid.DRIVE advances preparations for the 2026–2027 season with successful site initiation visits in Canada NewsroomThe 2025–2026 id.DRIVE studies reached the 10,000-patient recruitment milestone, bringing total enrolment over 40,000 participants since 2021. Newsroomid.DRIVE Site Investigators Meeting 2026: advancing study quality, operational efficiency and preparedness Newsroomid.DRIVE announces strategic expansion of study network to Canada Newsroomid.DRIVE
- [Governance](https://iddrive.eu/governance/) - WHAT IS A PUBLIC-PRIVATE PARTNERSHIP? Public-Private Partnerships (PPPs) consist of joint initiatives between the private sector (i.e., pharmaceutical companies, small-medium enterprises…) and public sector (i.e., universities, public health institutes, research organizations) in which resources and responsibilities are shared in order to achieve a common goal. This cooperative arrangement follows tailored governance models, which clearly define the roles
- [Participate](https://iddrive.eu/participate/) - HOW TO BECOME A COVIDRIVE STUDY SITE COVIDRIVE is calling for European hospitals, public health institutes and other research organizations to become a Study Contributor (study site) to the COVIDRIVE studies.Collaboration includes contributions to methodological and scientific discussions, collection and/or sharing data. COVIDRIVE provides technical and financial support.The benefits of becoming a Study Contributor include:Being
- [Contact](https://iddrive.eu/contact-2/)
- [CVE Reports](https://iddrive.eu/cve-reports/) - We will soon include COVIDRIVE’s Governance charter and other project deliverables
- [About us](https://iddrive.eu/about-us/) - Who we are Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras non scelerisque justo, id scelerisque velit. Cras non scelerisque justo, id scelerisque velit. Aliquam eget ligula libero. Suspendisse ac sollicitudin mi. Quisque ullamcorper fermentum tempus.Aliquam ornare, lectus eget varius vehicula, velit quam posuere nulla, mattis commodo dolor dolor et mauris. Suspendisse in eros enim. Pellentesque

## Events

- [IDWEEK 2026](https://iddrive.eu/event/idweek-2026/) - IDWEEK 2026
- [ERS Congress 2026](https://iddrive.eu/event/ers-congress-2026/) - European Respiratory Society
- [ISPE 42nd Annual meeting](https://iddrive.eu/event/ispe-42nd-annual-meeting/) - International Society for Pharmacoepidemiology
- [SEIMC conference](https://iddrive.eu/event/seimc-conference/) - Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
- [PIPELINE-EU project](https://iddrive.eu/event/pipeline-eu-project/) - PIPELINE-EU project(Home - PIPELINE), General Assembly 4; Palermo Italy; workshop
- [IDWeek 2025](https://iddrive.eu/event/idweek-2025/) - Annual meeting of the Infectious Diseases Society of America
- [ESWI Conference 2025](https://iddrive.eu/event/european-scientific-working-group-on-influenza/) - European Scientific Working Group on Influenza
- [ReSVINET 2026](https://iddrive.eu/event/respiratory-syncytial-virus-foundation-resvinet-2026/) - Respiratory Syncytial Virus Foundation ReSVINET 2026
- [ESCMID Global 2026](https://iddrive.eu/event/congress-of-the-european-society-of-clinical-microbiology-and-infectious-diseases/) - Congress of the European Society of Clinical Microbiology and Infectious Diseases
- [EFSPI Vaccine Statistic Workshop](https://iddrive.eu/event/european-federation-of-statisticians-in-the-pharmaceutical-industry/) - European Federation of Statisticians in the Pharmaceutical Industry

## Categories

- [Uncategorized](https://iddrive.eu/category/uncategorized/)
- [Newsroom](https://iddrive.eu/category/newsroom/)
- [Publications](https://iddrive.eu/category/publications/)